RVMD vs TNGX
RVMD: Revolution Medicines is a precision oncology company developing targeted therapies to treat RAS-addicted cancers through its proprietary research platform. TNGX: A precision oncology firm using a proprietary functional genomics platform to discover and develop targeted small-molecule therapies for genetically defined cancers.
Side-by-side fundamentals
| Metric | RVMD | TNGX | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $188.12 | $22.57 | |
| Market cap | $40.3B | $3.8B | |
| Net margin FY2025, SEC XBRL | n/a | -162.9% | |
| Operating margin FY2025, SEC XBRL | n/a | -178.4% | |
| ROE FY2025, SEC XBRL | -69.3% | -29.3% | TNGX higher |
| ROA FY2025, SEC XBRL | -48.0% | -25.5% | TNGX higher |
| Debt / equity as of 2026-09-02 | 0.40 | 0.00 | TNGX lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +39.0% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +35.9% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 1.05 | 1.33 | |
| 1-year return as of 2026-10-08 close | +293.4% | +226.6% | RVMD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.